Aurora Cannabis Inc
Aurora Cannabis Inc. is a Canadian cannabis company focused on medical cannabis products and related patient supply services. It operates across Canada, Europe, Australia, and New Zealand, with manufacturing and distribution assets that support regulated medical markets.
Kehitys
Liiketoiminta
Osuus liikevaihdostaCultivated cannabis products sold into regulated medical markets.
Processed cannabinoid products used by medical patients and dispensary channels.
Portfolio products sold under Aurora, MedReleaf, Pedanios, IndiMed, San Raf, and Whistler.
Import, distribution, and virtual pharmacy services supporting patient delivery.
Asiakkaat
Aurora sells primarily to medical cannabis patients through regulated distribution, pharmacy, and healthcare channels. It also serves medical market intermediaries such as importers, distributors, and licensed pharmacies in countries where the product is dispensed under strict regulatory controls.
Patients buying prescribed or authorized cannabis products for therapeutic use.
Pharmacies sourcing regulated cannabis for patient dispensing and fulfillment.
Channel partners that move product through country-specific regulatory systems.
Businesses buying compliant cannabis supply for regulated overseas markets.
Strategia
Aurora's strategy centers on regulated medical cannabis markets where product quality, GMP certification, and supply chain control matter. It is expanding direct control of distribution and pharmacy access in key markets such as the UK while using its brand portfolio and manufacturing footprint to support international growth.
Direct ownership of import, distribution, and pharmacy assets improves control over patient supply and channel economics.
Regulated markets often require high compliance standards, so certified production supports access and trust.
Diversifying across multiple medical cannabis markets reduces reliance on any single jurisdiction.
Maantiede
Aurora's business spans Canada, Europe, Australia, and New Zealand, with medical cannabis sales tied to regulated country-by-country market access. The company also has GMP-certified manufacturing in Canada and Germany and uses UK-based distribution and pharmacy assets to reach patients more directly.
Riskit
Aurora's business depends on regulated medical cannabis markets, so licensing, import rules, and product compliance can affect access to customers and supply chains. Geographic concentration in country-specific medical channels creates execution risk, while cannabis remains an industry with regulatory uncertainty, pricing pressure, and quality-control requirements.
- Regulatory and licensing dependenceVaikutus: KorkeaTodennäköisyys: Korkea
Medical cannabis sales require country-specific approvals, import permissions, and pharmacy distribution rules.
Kohdistuu - Supply chain and compliance disruptionVaikutus: KorkeaTodennäköisyys: Kohtalainen
The business relies on GMP-certified cultivation, processing, import, and last-mile delivery to patients.
Kohdistuu: Manufacturing and distribution operations
- Cannabis industry pricing pressureVaikutus: KeskitasoTodennäköisyys: Korkea
Competition and market maturation can compress pricing in medical cannabis categories.
Kohdistuu: Branded cannabis products
- Market concentration in regulated medical channelsVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Revenue depends on a relatively limited set of medical cannabis markets and channel partners.
Kohdistuu: UK and European medical cannabis markets
Kirjanpito
Harkinnanvaraiset erätCannabis products can lose value through aging, yield changes, or demand shifts, affecting reported cost of sales.
Vaikutus: Gross margin and inventory write-down risk
Sales may be recognized at shipment, delivery, or patient fulfillment depending on contract and channel structure.
Vaikutus: Quarterly revenue timing
Acquired brands, cultivation sites, and distribution assets may require impairment if expected cash flows weaken.
Vaikutus: Non-cash charges and book value
Management uses adjusted EBITDA to present operating performance excluding selected items.
Vaikutus: Comparability with GAAP earnings
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
IM Cannabis Corp.
IMCC · Medicinal Chemicals & Botanical Products
Aura Biosciences, Inc.
AURA · Biological Products, (No Diagnostic Substances)
Intercure Ltd.
INCR · Pharmaceutical Preparations
Trulieve Cannabis Corp.
TRLV · Medicinal Chemicals & Botanical Products
Ayr Wellness Inc.
AYRWF · Medicinal Chemicals & Botanical Products
CordovaCann Corp.
LVRLF · Services-Amusement & Recreation Services
Päivitetty: 28.9.2026